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Abstract
The employment of live attenuated vaccines has a long-standing record in
human and veterinary medicine. Most of the vaccines in current use were
empirically developed during the last century. Today, due to the great advances
in fields such as immunology and bioengineering, the rational development of
live attenuated vaccines becomes increasingly feasible. Moreover, live vaccines
can be used as carrier systems for heterologous antigens or therapeutic factors.
In each case, the development of a recombinant live attenuated vaccine is
a complex task where properties such as targeting specificity, antigen synthesis,
antigen release, and safety aspects have to be integrated. A range of such
recombinant vaccine candidates have successfully been tested in the clinics,
but very few have been approved so far. In many cases, further optimization of
such vaccines is necessary with regard to their efficacy and safety profiles. In the
present chapter, we focus on current strategies which are employed for the
development of new and the optimization of first generation recombinant live
vaccines based on bacteria and viruses.
5.1 Introduction
Vaccination with live attenuated pathogenic viruses has a long tradition, although
few people are aware of this. Already in the fifth century AD, variolation, the
vaccination against smallpox virus with material from pustules of infected people,
was practiced in China and later in India as well as in Japan and Europe (Mazumdar
2003). The material was applied intradermally or nasally. At a pending smallpox
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epidemic, even the grandchildren of George I, king of England, were variolated
after rudimentary safety and efficacy trials using death-sentenced prisoners and
orphans for testing. Although highly protective, variolation never reached general
compliance in the Western world partly because a certain death toll had to be paid
using this method. It was not before the groundbreaking experiment by Edward
Jenner in 1796 that vaccination was generally accepted. Jenner prevented smallpox
disease in a 13-year-old boy by preinoculation with cowpox virus and established
convincingly the principle of immunization by the use of active agents, at this time
without knowledge about the nature of the immunogen or the immune system.
Following the discovery of pathogenic bacteria, Louis Pasteur pioneered the devel-
opment of several vaccines. In 1879, he generated the first live attenuated bacterial
vaccine by extended culture of fowl cholera bacteria, which could be applied to
chicken without causing disease but preventing them from infection with a virulent
strain (Pasteur 1880). This discovery marks the starting point for the development
of live attenuated vaccines (LAV). Within the next 20 years at the end of the
nineteenth century, a number of further vaccines quickly appeared, for example,
anthrax and rabies vaccines developed by Pasteur or human vaccines against
typhoid fever, cholera, and plague (Makela 2000). Since then, many LAV for
human and animal use were developed until today, including live attenuated
bacteria, fungi, parasites, and viruses. Such vaccines continue to have a tremendous
impact in the prevention of infectious diseases despite a number of other vaccine
classes have been introduced over time. This reflects unique characteristics of
LAV, which are unmet by other vaccines thus far with respect to the induction of
protective immune responses against specific pathogens (Table 5.1).
One of the hallmarks of LAV is that they efficiently target immune inductive
sites during their limited infection cycle in the host. In contrast to the majority of
other currently used vaccines, which preferentially induce antibody-mediated
immune protection, LAV are capable of stimulating cellular immunity as well.
However, potential risks such as virulence reversion or side effects particularly
in immunocompromised individuals led to the replacement of some of the success-
ful LAV in the past and raised continuously standards for approval of new live
Table 5.1 Pros and cons of current LAV
Pros Cons
Simulation of natural infection course Risk of reversion to virulence
Induction of cellular and antibody responses Risk for immunocompromised individuals
Induction of mucosal and systemic immunity Risk of environmental release and spreading
Mucosal administration routes Reactogenicity
High efficacy, single or few doses required High costs during development
Long-lasting immunity Short shelf-life
No adjuvant required Regulatory hurdles
No preservative required Public resistance to genetically modified LAV
Low production cost
Easy transport and storage
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vaccines especially for human use (Table 5.1). For animals, benefit risk assessments
of LAV often have a more positive outcome. The comparatively small number of
approved human LAV is opposed to a relatively large number of veterinary LAV
against a whole array of pathogens today.
The advent of recombinant DNA technology opened up the possibility of
targeted modification of microbes. This paved the way for rational attenuation
of LAV, rendering them nonpathogenic even in the absence of a functional host
immune system and inert to changes in diet, commensal flora, or other individual
traits. In addition, the use of LAV as delivery systems for foreign antigens derived
from other pathogens or therapeutic molecules is now possible. Meanwhile,
a considerable number of such recombinant LAV advanced into clinical testing
or even have obtained marketing authorization. Notably, most approved recom-
binant LAV thus far are veterinary vaccines (Meeusen et al. 2007). However,
the rapidly expanding knowledge about host–microbe interactions and recent
technological advances, such as genome sequencing, global expression analysis
techniques, as well as high end gene synthesis, will open up completely new ways
to rationally design LAV as such or for recombinant vaccine delivery. Eventually,
it will be possible to develop a new generation of LAV tailored for specific appli-
cations with an excellent safety and efficacy profile. Thus, harnessing the potential
of LAV to induce all arms of the immune system, these vaccines probably will
provide new options in the fight against major threads to human and animal health.
Depending on the vector system of choice, “vaccine cargo” of different nature,
size, and amount can be delivered. Whereas viral vaccine vectors in most cases
will carry the genetic information of foreign antigens in order to mediate their
expression in the host cells, other microbial vector systems offer more flexibility
with respect to delivery and release of foreign antigens. Such delivery systems
have been designed either to directly produce antigenic peptides or to deliver
antigen-encoding nucleic acids to host cells.
5.2 Bacterial LAV and Their Use for Vaccine Delivery
5.2.1 Bacterial LAV in Use Today and Novel Attenuation Strategies
The majority of pathogenic bacteria either colonize or transit mucosal compart-
ments during infection. In order to prevent bacterial infection and spreading of
disease, the induction of mucosal immune responses is of particular importance.
Bacterial LAV are regarded as prototype mucosal vaccines capable to induce
mucosal as well as systemic immune responses (Dietrich et al. 2003; Kochi et al.
2003). In addition, mucosal vaccines often simplify administration, thereby enhanc-
ing safety and reducing costs of vaccination. Originally, most bacterial LAV were
empirically derived from pathogenic isolates. Undirected methods such as passag-
ing or chemical or physical mutagenesis were employed in order to reduce viru-
lence of such strains yet retain their ability to transiently colonize host tissues and
induce protective immunity. Such methods were stepwise replaced since the 1980s
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by directed mutagenesis. Currently, only three bacterial LAV are licensed
for human use, namely, Bacillus Calmette-Guerin (BCG), Salmonella enterica
serovar Typhi (S. typhi) strain Ty21a, and Vibrio cholerae (V. cholerae) strain
CVD 103-HgR. In contrast, a wide range of bacterial LAV are utilized in veterinary
medicine.
In case of the parenteral tuberculosis (TB) vaccine, BCG was passaged in culture
medium for more than a decade and gave rise to the attenuated variant of the
original Mycobacterium bovis isolate in 1919 (Calmette et al. 1927). Since then,
BCG has been administered to about four billion people being therefore the most
widely used bacterial LAV for human use thus far. However, BCG alone is unable
to prevent pulmonary TB in adults. Only newborns can be temporarily protected
this way, except HIV-infected babies (Mansoor et al. 2009). In order to prevent
a resurgence of TB due to reasons such as increasing occurrence of multidrug-
resistant Mycobacterium tuberculosis strains or the prevalence of HIV, new
vaccines are urgently needed. Improved recombinant BCG alone or as part of
prime–boost approaches constitutes an important route of TB vaccine development
(Kaufmann et al. 2010). As a replacement of BCG, also M. tuberculosis-derived
attenuated variants are tested (Gonzalo-Asensio et al. 2008). As veterinary vaccine,
BCG has been used successfully against bovine TB (Buddle et al. 2006).
The human LAV against typhoid fever S. typhi Ty21a and cholera V. cholerae
CVD 103-HgR are orally administered. The vaccine strain S. typhi Ty21a has been
obtained in the 1970s by chemical mutagenesis with nitrosoguanidine (Germanier
and F€urer 1975). Colonies were screened for their sensitivity to galactose due
to a lack of the enzyme uridine diphosphate galactose epimerase (galE). The
reasoning was that such bacteria would then be deficient of the polysaccharide
coat and therefore rendered vulnerable to the immune system. Unintentionally,
a number of additional attenuating mutations were introduced this way (Germanier
and F€urer 1983).
About 10 years later, the cholera vaccine strain V. cholerae CVD 103-HgR
was more rationally derived from the pathogenic isolate by genetic engineering
(Levine and Kaper 1993). Gene ctxA encoding the toxic A subunit of the cholera
toxin was deleted causing sufficient strain attenuation while leaving the expres-
sion of the immunogenic B subunit unaffected. Furthermore, gene hlyA encoding
hemolysin was disrupted by integration of a mercury resistance gene, which
allows discrimination from wild-type strains.
In veterinary medicine, since decades, many LAV against bacterial diseases
are in use, which were established in most cases by undirected mutagenesis.
Most prominent examples are vaccines against salmonellosis for poultry, swine,
and cattle. Various serovars of Salmonella enterica are causative agents of either
enteritis or septicemia in animals. In turn, contaminated animal-derived food
products are the main sources for human Salmonella infections (Barrow 2007).
Attenuated Salmonella vaccine strains established by chemical mutagenesis have
been introduced into veterinary practice in the 1970s and are often in use until today
(Linde et al. 1974; Meyer et al. 1993). Directed attenuation by genetic engineering
became feasible in the 1980s. A number of suitable gene targets were identified,
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belonging mainly to metabolic pathways, regulatory systems, or virulence determi-
nants. Interference with synthesis of aromatic amino acids by deletion of gene
aroA (encoding 5-enolpyruvyl shikimate-3-phosphate synthase) proved to be
an excellent strategy for safe attenuation while retaining immunogenicity of
a S. typhimurium strain (Hoiseth and Stocker 1981). This concept was subsequently
transferred for attenuation to a number of other bacteria, such as Aeromonas
salmonicida (Vaughan et al. 1993), Yersinia enterocolitica (Bowe et al. 1989),
Pasteurella multocida (Homchampa et al. 1992), Escherichia coli (Fan et al. 2004),
and Streptococcus equi (Jacobs et al. 2000), of which several strains were success-
fully commercialized as LAV for animal use. As a strategy to reduce the likelihood
of virulence reversion, e.g., due to unwanted acquisition of complementing
DNA sequences, attenuation of multiple genes was proposed. Mutations of genes
aroA and aroD, both part of the same metabolic pathway, were introduced into
vaccine strains of S. typhi (Chatfield et al. 1992b) and Shigella flexneri (Verma
and Lindberg 1991).
A prerequisite for the use of animal vaccines is often the ability to differentiate
infected from vaccinated animals (DIVA concept) (van Oirschot 2001). This can be
achieved by deletion of an immunogenic antigen such that vaccinated animals are
seronegative for it but not for other protective vaccine antigens. In the case of
Actinobacillus pleuropneumoniae, the causative agent of porcine pleuropneumonia,
sequential deletion of six genes gave rise to an appropriate attenuated candidate
vaccine strain, which also complies to the DIVA concept (Maas et al. 2006).
However, the removal of virulence determinants often gives rise to strains,
which fail to transiently colonize immune inductive sites and therefore do not
induce potent immune responses. In accordance, the so-called strategy of regu-
lated delayed attenuation was established recently in order to circumvent this
problem (Curtiss III et al. 2009). Here, the vaccine strain is designed in a way
that the invasive phenotype of the strain is retained during the initial phase of
vaccination until immune inductive sites have been colonized. Subsequently, due
to the lack of a particular substrate in vivo, the invasive phenotype of bacteria
fades before acute disease is elicited. Proof of concept was established with
mutant strains lacking either genes galE or pmi (phosphomannose isomerase)
(Curtiss III et al. 2010). Such mutants are attenuated due to the lack of func-
tional lipopolysaccharide (LPS). However, when grown in the presence of either
galactose or mannose, respectively, these mutants synthesize LPS and are able
to colonize host tissue upon oral administration. Since both sugars are not
present in vivo, LPS synthesis is subsequently abrogated and bacteria rendered
vulnerable to host defenses.
Finally, after successful establishment and clinical testing of a bacterial
LAV, careful risk assessment is necessary prior to vaccine registration (Frey
2007). Despite safety concerns for the approval of genetically modified LAV at
present, rationally engineered strains will probably gain acceptance in the future
due to the high degree of molecular definition in addition to their superior
performance.
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5.2.2 Recombinant Bacterial LAV for Vaccine Delivery
Bacterial LAV have a proven track record of efficacy in human and veterinary
medicine. In addition, the understanding of LAV interaction with the host immune
system has greatly advanced (Kaufmann 2007). This is an excellent basis for the
development of a next generation of bacterial LAV. Existing vaccines will even-
tually be replaced by refined strains, in which, in addition to defined attenuation,
a number of other features are rationally designed like modulated expression of
immunogenic components (Fig. 5.1). Furthermore, recombinant DNA technology
provides the possibility to program such strains at the same time as delivery
system for foreign antigens, nucleic acid-based vaccines, or therapeutic molecules
(Fig. 5.1). By now, a wide range of bacteria are explored for these purposes. In this
case, distinct properties of bacterial species can be harnessed or diverted depending
on the specific needs for the spectrum of medical applications (Fig. 5.2). Nonpatho-
genic bacteria such as food-derived or commensal lactic acid bacteria are attractive
for the delivery of vaccines and therapeutics especially via the mucosa because they
are considered of being generally safe (Wells and Mercenier 2008). In contrast to
invasive attenuated bacteria, they do not actively enter and replicate inside host
cells. Therefore, release of heterologous antigens from such bacteria occurs primar-
ily in the extracellular space (Fig. 5.2a). In accordance, they mainly stimulate
induction of antibody responses in several vaccination models. However, extracel-
lular LAV can also be engineered to directly inject heterologous antigens into the
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Fig. 5.1 Next-generation bacterial LAV for vaccine delivery. The development of a new bacterial
LAV for the delivery of a specific vaccine is a complex and individual process for each applica-
tion. First, a suitable bacterial carrier strain has to be selected and to be attenuated in a defined
manner (red symbols). In order to potentiate vector-directed immune responses (if intended) or to
provide optimal adjuvant activity components of the strain can be modulated (blue symbols).
Examples for modulation could be overexpression of immunogenic surface proteins or the
removal of anti-apoptotic genes from the carrier strain in order to strengthen cross-priming. The
synthesis and delivery of heterologous protein and/or nucleic acids requires precise programming
of the vaccine strain (green symbols). Expression cassettes are either located on plasmids or
integrated into the chromosome. Expression determinants and coding sequences can be optimized.
Finally, release and transfer of vaccine components from bacteria to the immune cells can either be
achieved by secretion or bacterial disintegration
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host cell cytosol in order to induce cytotoxic T-cell responses (Fig. 5.2a). This was
first demonstrated by employing an extracellular Yersinia pseudotuberculosis car-
rier strain mediating the cytosolic delivery of listeriolysin O (LLO), a protective
antigen of Listeria monocytogenes (L. monocytogenes), via its type III secretion
apparatus (Russmann et al. 2003). More often, recombinant LAV have been derived
from bacteria capable of invading host cells, such as Salmonella spp., L.
monocytogenes, or Shigella flexneri (Curtiss III 2002; Kotton and Hohmann
2004). In case of Salmonella, subsequent to cellular invasion, bacteria reside
naturally inside a phagosome. They subvert this compartment into a protected
niche for proliferation. Presentation of heterologous antigens expressed by
attenuated Salmonella that undergo disintegration in this compartment is therefore
restricted mainly to the MHC-II pathway leading to CD4 T-cell activation
(Fig. 5.2b). In contrast, L. monocytogenes or Shigella flexneri escape the vacuolar
compartment soon after cellular uptake and replicate inside the cytosol. Thus, upon
carrier disintegration, vaccine cargo can be directly released into the cytoplasm
(Fig. 5.2c). This allows presentation of heterologous antigens via MHC-I molecules
to CD8 T-cells. However, the great advances in understanding the molecular
mechanisms, which lead to a particular bacterial function such as host cell invasion,
a b
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Fig. 5.2 Delivery of heterologous antigens or nucleic acids by bacterial LAV. (a) Heterologous
antigen delivery by extracellular bacteria. Antigens can either be released outside the host cell or
delivered into the host cell cytoplasm, e.g., by a type III secretion system. (b) Delivery of
heterologous antigens from bacteria which are restricted to an intracellular vacuole, e.g., Salmo-
nella. Antigens can either be targeted to the vacuole or to the cytosol. (c) Bacteria capable of
vacuolar escape can deliver heterologous antigen directly to the cytoplasm of the host cell upon
degradation or by secretion
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intracellular residence, etc., will allow more and more to interchange the underlying
molecular systems between bacterial species in order to tailor bacterial LAV
precisely for specific applications.
In the present chapter, we will focus especially on Salmonella vaccine vectors in
order to exemplify major improvement strategies for the development of bacterial
LAV in general. Salmonella LAV constitute promising vectors for heterologous
antigens because after oral administration, they are able to invade and colonize
mucosal and systemic immune inductive compartments at the same time. Thus,
long-lasting humoral and cellular immune responses have been induced against
a wide spectrum of antigens delivered by Salmonella LAV (Galen et al. 2009;
Kwon et al. 2007; Moreno et al. 2010). In addition to the selection of a suitable
vector strain which meets the balance between immunogenicity and safety (as
discussed before), the strategy of heterologous antigen synthesis and delivery has
to be carefully considered for each antigen and the anticipated immune response
(Galen and Levine 2001; Kotton and Hohmann 2004). Definition and implementa-
tion of such a strategy can be a very challenging and complex process.
5.2.2.1 Level and Timing of Antigen Expression
For the induction of strong antibody responses, high amounts of antigen are
required in most cases, whereas for cellular responses, moderate antigen delivery
may suffice. Therefore, strong constitutive promoters were used initially for
the expression of heterologous antigens by bacterial LAV (Brown et al. 1987).
However, even when achieved at all, such high-level expression of antigen often
constitutes a serious burden for the vaccine strain, which reduces its ability of tissue
colonization and to induce immune responses. As a solution to this problem, the use
of in vivo inducible (IVI) promoters was proposed which are derived from genes
that become activated under conditions encountered at certain stages of the coloni-
zation course. At first, the nitrite reductase promoter (PnirB) of E. coliwas employed
which is induced by intestinal hypoxia (Chatfield et al. 1992a). Subsequently,
a number of additional IVI promoters were tested for the expression of heterologous
antigens (Hohmann et al. 1995; Stratford et al. 2005; Valdivia and Falkow 1997).
Each individual promoter differs in the timing and level of antigen expression and
consequently influences the antigen-specific immune induction (Bumann 2001).
An alternative approach was developed in the Curtiss lab which was named
“regulated delayed synthesis of antigens” (Xin et al. 2008). Here, antigen produc-
tion is retarded due to the arabinose-dependent expression of a repressor protein
driven by the PBAD promoter in vitro (Guzman et al. 1995). Upon vaccine adminis-
tration, the repressor expression ceases due to the lack of arabinose in the gastroin-
testinal tract of the mice, thus relieving the repressor blockade of the antigen
expression cassette. For both strategies, the use of IVI promoters or the employment
of a regulated delayed synthesis system, the time point of antigen synthesis and the
expression level is fixed and cannot be tuned during vaccination. We therefore
have recently tested the suitability of substrate-inducible promoters for the deli-
berate onset and adjustment of reporter gene expression by bacterial LAV in vivo
(Loessner et al. 2007, 2009). Such promoters constitute a new option for inducible
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antigen expression in a controlled manner in vivo, a concept that was termed
“in vivo remote control” (IVRC). However, since for optimal induction of immune
responses, such as Th1-type responses, continuous antigen expression is necessary
(Griffin and McSorley 2011), prolonged administration of inducer substrate
would probably be required when IVRC promoters are employed.
5.2.2.2 Expression Cassette
Plasmids harboring expression cassettes are often used for conversion of vaccine
strains into delivery vehicles for heterologous antigens. The main advantage of
plasmids is that they can be easily manipulated in E. coli and subsequently
transferred into vaccine strains. In addition, multicopy plasmids mediate elevated
levels of antigen synthesis in comparison to single-copy chromosomal expression
cassettes. However, episomal plasmid replication constitutes a metabolic burden
for bacteria, thus further attenuating the vaccine strain (Covone et al. 1998). More-
over, plasmid maintenance is often achieved by antibiotic selection in vitro. In
the absence of this selective pressure in vivo, plasmids are often lost from the
proliferating bacteria. In order to ensure stability of the plasmid transformants
without the need of antibiotic selection, so-called balanced lethal systems have
been established (Curtiss III et al. 1990). Such systems rely on host strains with
a chromosomal deletion of an essential metabolic gene. The defect of this gene
is complemented on the expression plasmid, therefore ensuring stable plasmid
propagation. An alternative approach is the use of so-called addiction systems for
plasmid stabilization (Galen et al. 1999).
In contrast, integration of expression cassettes into the bacterial genome ensures
stable propagation. However, genomic integration of single expression cassettes
often does not mediate synthesis of sufficient antigen levels. A solution to this
problem would be multiple integrations of the same expression cassette. However,
in recombination competent vaccine strains such repetitions of homologous sequ-
ences are often instable due to undesired recombination events. In accordance,
removal of recombinases from vaccine strains is an important advancement for the
stabilization of such repetitive chromosomal integrations and also plasmid DNA
(Zhang et al. 2011).
Nowadays, gene synthesis is rapidly replacing cloning procedures for the
establishment of antigen expression cassettes (Kindsmuller and Wagner 2011).
Thus, the fine tuning of promoter elements or the optimization of coding sequences,
e.g., the adjustment of codon usage, has been accelerated tremendously.
5.2.2.3 Antigen Release
Several properties of the vaccine strain, such as cellular tropism, bacterial virulence
mechanisms, and type of attenuation, predetermine the time point and location
of antigen delivery (Fig. 5.2) (Cheminay and Hensel 2008; Loessner et al. 2008).
Since requirements for protective immune responses against pathogens differ,
targeting of heterologous antigens into different presentation pathways is neces-
sary. Thus, the choice of the right attenuated vaccine strain is important to accom-
plish such efficient targeting. Heterologous antigens synthesized by bacterial LAV
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have to be released from the bacteria in order to be recognized by immune cells.
Gram-negative bacteria lacking gene asd encoding the aspartate-semialdehyde
dehydrogenase undergo cell death in environments lacking diaminopimelic acid
(DAP). Since DAP is absent in the gastrointestinal tract, orally applied bacteria
deficient of asd quickly lyse in vivo (Curtiss III 1978). During DAP-less death, the
bacterial cell wall spontaneously bursts, and cytoplasmic cellular contents such as
protein and nucleic acids are efficiently released (Loessner et al. 2006). In contrast,
other lethal attenuations, such as deficiency of thyA (thymidylate synthase) in
thymine or thymidine-deprived environments, do not cause rupture of the bacterial
cell, and therefore, no immediate release of cytoplasmic material occurs. Hence,
subsequent slow degradation of bacterial carcasses may prevent release and pre-
sentation of heterologous antigen. As alternative to strain attenuation, inducible
lysis systems have been developed which mediate efficient release of cytoplasmic
antigen or nucleic acid from ruptured bacterial cells. For instance, bacteriophage
lysis determinants have been employed for this purpose (Jain and Mekalanos 2000).
The use of lysis protein E derived from phage phiX174 has already been employed
for some time to prepare bacterial cell envelopes devoid of cytoplasmic content to
be used for vaccination, so-called bacterial ghosts (Jalava et al. 2003). The employ-
ment of such lysis determinants for the release of heterologous antigens from
a bacterial vector strain necessitates its tightly regulated inducible expression
in vivo. This was achieved by linking lysis gene E to the arabinose-inducible
PBAD promoter, suitable for IVRC (see above) (Loessner et al. 2007), or more
recently to quorum sensing or iron-regulated promoters (Guan et al. 2011; Silva
et al. 2010). Similar to DAP-less death, lysis protein E causes rupture of bacterial
cells by interference with cell wall synthesis (Bernhardt et al. 2000).
Another lysis strategy was established by the Curtiss lab, termed “regulated
delayed lysis system” (Kong et al. 2008). In this work, a Salmonella double mutant
strain was constructed with chromosomal deletions of two genes involved in cell
wall biosynthesis, asd andmurA. Plasmid-encoded complementing genes are linked
to the arabinose-inducible PBAD promoter which was kept active by the presence of
arabinose during culture. Upon oral vaccine administration, expression of both
genes ceases due to absence of arabinose in vivo and bacteria disintegrate. Thus,
this system confers attenuation and mediates antigen release at the same time.
Whereas cytoplasmic antigens are released at once from bacteria undergoing
lysis, a viable bacterial carrier can be engineered to release antigen continuously by
the use of a suitable secretion system. A variety of one-component or multicom-
ponent secretion systems have been employed for this task. As single-component
systems, so-called autotransporters, such as E. coli AIDA-I (Maurer et al. 1997),
are suitable for translocation of passenger antigens across the gram-negative
cell envelope. Stable display of antigens on the surface of a Salmonella vaccine
strain via the E. coli AIDA-I efficiently induced cellular immune reactions (Kramer
et al. 2003).
Similarly, the E. coli alpha-hemolysin (HlyA) secretion apparatus, belonging
to the group of type I secretion systems, is fully active in Salmonella vaccine
strains and has successfully been used for the delivery of a number of antigens
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(Gentschev et al. 2002). The system is composed of three proteins which mediate
translocation of passenger antigens fused to the HlyA signal peptide directly to the
extracellular medium.
So-called type III secretion systems (T3SS) are used by bacterial pathogens for
the delivery of virulence factors across eukaryotic membranes (Hueck 1998). T3SS
are very complex and cannot easily be transferred from one bacterial vector to
another. However, naturally T3SS harboring vaccine strains can be efficiently
subverted for the delivery of antigens directly into the cytosol of host cells
(Russmann et al. 1998). This way, antigens can be targeted into MHC-I presentation
pathway by extracellular or phagosome-restricted bacterial vectors (Russmann
et al. 2003; Panthel et al. 2008). Nevertheless, the specificity of the T3SS for
particular virulence factors renders these systems difficult for a general applica-
tion of antigen secretion by gram-negative bacterial vaccine strains. In contrast,
secretion systems from gram-positive bacteria are often less restricted to particular
virulence factors and might allow the continuous secretion of antigens from the
vaccine carrier (Buist et al. 2006).
5.2.2.4 Delivery of Nucleic Acid Vaccines
Already some time ago, the capability of bacteria to deliver nucleic acids into
mammalian cells was discovered (Schaffner 1980). Meanwhile, bacteria-mediated
transfer of plasmid DNA encoding vaccine antigens or therapeutic molecules was
demonstrated in experimental animal models of infectious diseases, tumors, and
gene deficiencies (Becker et al. 2008; Daudel et al. 2007; Loessner and Weiss
2004). Bacteria, competent to access the host cell cytoplasm, have been observed
to display the highest transfer efficiency for nucleic acids (Courvalin et al. 1995;
Dietrich et al. 1998; Sizemore et al. 1995). However, bacteria restricted to an
intracellular vacuolar compartment such as Salmonella are also capable to mediate
DNA transfer to a certain extent by an unknown mechanism (Darji et al. 1997). The
use of an S. typhimurium strain lacking ssrAB, two essential genes for maintenance
of phagosomal integrity during intracellular growth, improved the DNA delivery
capacity of the vaccine strain (Bai et al. 2011). In addition, extracellular bacteria
can mediate DNA delivery into mammalian cells by a conjugational apparatus
(Kunik et al. 2001; Waters 2001). In comparison to other DNA delivery systems,
bacterial vectors have a nearly unlimited capacity with regard to size. For instance,
infectious virus could be reconstituted by the delivery of the complete genome of
murine cytomegalovirus (MCMV) by a Salmonella vaccine strain into mammalian
cells (Cicin-Sain et al. 2003). Specific silencing of mammalian genes was achieved
with an engineered E. coli strain which could mediate the delivery of short hairpin
RNA (shRNA) (Xiang et al. 2006). However, several bottlenecks have been
identified which counteract the bacterial delivery of nucleic acids into mammalian
cells. Cellular defense mechanisms such as autophagy (Ogawa et al. 2005), bacte-
ria-induced cellular activation, or cell death (Fink and Cookson 2007) are factors
that can restrict transfer efficiency. Nevertheless, bacteria-mediated gene transfer
remains an attractive alternative for antigen delivery. Since the antigen is produced
by the eukaryotic cells, obstacles like inefficient protein folding, posttranslational
5 Employing Live Microbes for Vaccine Delivery 97
modification, or secretion can be circumvented. In addition, the bacteria represent
a powerful adjuvant that helps to trigger efficacious immune responses.
5.2.2.5 Delivery of Tumor Vaccines and Adjuvant Molecules
The best examples for successful bacteria-mediated DNA vaccination are the
experiments by the Reisfeld group using oral Salmonella vectors for delivery of
anticancer vaccines (Reisfeld et al. 2004). Vaccine-mediated restriction of tumor
angiogenesis was one approach of this work. As one of their targets, they used the
vascular endothelial growth factor receptor (VEGFR2), also referred to as FLK-1.
This molecule is not expressed by tumor cells but highly expressed on endothelial
cells of growing tumor capillaries. When a eukaryotic FLK-1 expression plasmid
was transferred orally by Salmonella to mice, animals were protected against
subsequent challenge with different tumors, such as the MC38 colon carcinoma
(Niethammer et al. 2002). Even 10 months after the vaccination, animals could
resist such a challenge. Also, the use of so-called minigenes for expression of
FLK-1 epitopes was successful to restrict tumor growth due to CD8 T-cell response
(Luo et al. 2007). The advantage of such minimal coding sequences is that the
probability of mutations is reduced and antigen delivery by bacteria is facilitated.
Another possible strategy is the use of a DNA vaccine for co-expression of
cytokines or chemokines in conjunction with the antigen. IL-18 is a multifunctional
cytokine and is able to improve tumor antigen presentation by DCs. Co-expression
of the tumor antigen Fos-related antigen (Fra-1), which is overexpressed by many
epithelial carcinomas, together with IL-18 mediated the reduction of metastases
(Luo et al. 2005). In another approach, inhibition of angiogenesis was achieved
by Salmonella-mediated oral delivery of the apoptosis protein survivin and the
chemokine CCL21 in parallel, which attracts activated DCs and naı¨ve T cells to the
tumor site. Vaccination prevented pulmonary tumor growth and metastases and
reduced the growth of already established tumors (Xiang et al. 2005). The expres-
sion of fibroblast activation protein (FAP) can be determined in approximately 90%
of human epithelial tumors and is specific for stromal fibroblasts in solid tumors.
The Salmonella-mediated delivery of a DNA vaccine against FAP enhanced the
efficacy of doxorubicin chemotherapy and suppressed spontaneous metastases.
In addition, this combination therapy inhibited tumor angiogenesis and reduced
the expression of proliferative factors by the tumor microenvironment (Liao
et al. 2009).
Attenuated strains of the gram-positive bacteria L. monocytogenes have also
been studied in context of tumor vaccines. The bacteria are able to infect phagocytic
and nonphagocytic cells and can spread in the body without being attacked by
an antibody response. L. monocytogenes infection stimulates strong innate and
adaptive immune response, rendering it an efficient vaccine vector candidate
(Barbuddhe and Chakraborty 2008). In addition, the cytosolic intracellular resi-
dence of the bacteria favors a CD8 T-cell response that is necessary for the
generation of antitumor immunity. To ensure bacterial secretion of the specific
antigen, in most cases, the antigen is fused to a secretory bacterial protein such as
LLO. One example of a L. monocytogenes tumor vaccine is a strain producing the
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human papillomavirus (HPV) antigen E7, which is associated with cervix and head
and neck cancer (Gunn et al. 2001). In animals, this vaccine induces immune
responses against E7 and causes regression of tumors which express the E7.
In a phase I clinical trial, this vaccine was demonstrated to be safe in humans
(Maciag et al. 2009). From 13 patients, five had progressed, seven had stable
disease, and one qualified as a partial responder. Increased survival of patients
was observed, from 180 to 347 days, and three patients were still alive 3 years
after treatment. L. monocytogenes was also employed for the delivery of
a prostate cancer vaccine. L. monocytogenes was engineered to deliver a LLO–PSA
fusion protein. In a mouse model, it was demonstrated that this vaccine is immuno-
genic and causes regression of established PSA-expressing tumors (Shahabi
et al. 2008).
5.2.3 Tumor-Targeting Bacteria
Apart from being powerful carriers for novel vaccination strategies, particular
bacteria show also a potential to be used in cancer therapy. This is due to their
ability to target and colonize tumors upon systemic administration (Leschner and
Weiss 2010). Among the bacteria able to target tumors are anaerobics like
Clostridia and Bifidobacteria as well as facultative anaerobics like Salmonella
and E. coli. Interestingly, already in the nineteenth century, several physicians
observed that cancer patients who caught an infection sometimes were cured
from the tumor (Coley 1893). Even intentional infection of cancer patients medi-
ated successful tumor cure in some cases; however, in most patients, the infection
was fatal, and therefore, this approach was abandoned at that time. Today, with new
options for attenuation and programming of bacteria, the development of cancer
therapeutics based on living bacteria should become feasible.
Since most bacterial strains used for cancer therapy are pathogens, they first of
all have to be attenuated. Some strains are under investigation that have been tested
already as vaccine carriers like SL7207 (DaroA, DhisG) (Leschner et al. 2009;
Westphal et al. 2008; Yu et al. 2004), BRD509 (DaroA, DaroD) (al-Ramadi et al.
2009; Yoon et al. 2007), and SL3261AT (DaroA) (Avogadri et al. 2008; Yang et al.
2008). Such strains are deficient in synthesis of aromatic amino acids. Besides,
there are also strains attenuated especially for the tumor-targeting purpose. One
example is the Salmonella strain A1-R that was rendered auxotrophic for leucine
and arginine and reisolated from tumors to enhance tumor specificity. It colonizes
various human tumors and metastases in nude mice but is cleared rapidly from other
organs (Hayashi et al. 2009a; Hayashi et al. 2009b; Kimura et al. 2010; Nagakura
et al. 2009; Zhao et al. 2007, 2005, 2006). Another Salmonella strain considered to
display an improved safety profile is VNP20009 (DpurI, DmsbB). It produces
a modified lipopolysaccharide and thus induces dramatically diminished levels
of TNF-a in human peripheral leukocytes (Low et al. 1999). Unfortunately,
VNP20009 did not readily colonize tumors of patients in phase I trials (Heimann
and Rosenberg 2003; Toso et al. 2002). Possibly this strain is overattenuated since
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TNF-a was shown to play an important role in the invasion process of Salmo-
nella into tumors (Leschner et al. 2009). Thus, presently, the major challenge in
developing tumor-targeting bacteria is proper attenuation of the strain without
restricting its capability to colonize the tumor tissue.
Apart from their inherent antitumor effect, some bacteria could be used as
carriers to deliver therapeutic agents directly into the cancerous tissue. Different
classes of molecules have been tested. One class represents immune modulatory
molecules that should enhance the immune response toward the tumor or directly
kill cancer cells. IL-2, IL-18, CCL21, LIGHT, and Fas ligand have been tested
in this context (al-Ramadi et al. 2008, al-Ramadi et al. 2009; Loeffler et al. 2007,
Loeffler et al. 2008a, b, 2009; Saltzman et al. 1996, 1997; Sorenson et al. 2008a, b).
Toxic agents are another possibility to enhance anticancer effects of bacteria. For
instance, the bacterial toxin cytolysin A resulted in strong reduction of tumor
growth when expressed by tumor-colonizing S. typhimurium (Nguyen et al. 2010;
Ryan et al. 2009). A third class of molecules are so-called prodrug-converting
enzymes that convert nontoxic prodrugs into toxic substances. For example,
thymidine kinase of the herpes simplex virus or E. coli cytosine deaminase has
been used in this context (King et al. 2002; Nemunaitis et al. 2003; Pawelek et al.
1997; Royo et al. 2007). Tumor therapeutic bacteria mediating delivery of eukary-
otic expression plasmids for therapeutic factors or interfering RNA species are
also in development. In tumor therapeutic approaches, the use of proteins like
thrombospondin-1, endostatin, Fms-like tyrosine kinase 3 (Flt3) ligand, but also
the E. coli prodrug-converting enzyme purine nucleoside phosphorylase or apoptosis-
inducing proteins (TRAIL and Smac), led to efficient treatment of various tumors
in mice (Fu et al. 2008a, b, c; Lee et al. 2004, 2005; Yoon et al. 2007). Similarly,
siRNAs on eukaryotic plasmids targeting Stat-3 or the antiapoptotic protein bcl-2
showed their potential to be used in the treatment of tumors. Although promising,
the mechanism leading to the effect is unclear. Salmonella are only rarely found
inside of tumor cells or other host cells (Agorio et al. 2007; Loessner and Weiss
2007; Pawelek et al. 1997). Therefore, the question which cells can be the target for
gene transfer still has to be answered. When constructing an efficacious anticancer
bacterium, the regulation of therapeutic molecule expression is crucial. The use of
particular promoters allows to predetermine the exact onset of therapeutic treatment
as well as its termination, e.g., via the expression of suicide genes (Loessner et al.
2007). Therefore, inducible promoters like the PBAD promoter mentioned before
enable to start the expression upon administration of the inducer substance at any
desired time point (Loessner et al. 2007). Furthermore, tumor-specific promoters
that exclusively drive protein expression inside of the neoplasia but not in any other
tissue of the host are an important aspect to avoid side effects on healthy organs
(Arrach et al. 2010; Leschner et al. 2011). Bacteria-mediated tumor therapy is often
met with skepticisms despite the undisputed success in experimental and preclinical
models. Although it will still require many iterative steps until it is converted into
a general applicable therapeutic strategy, it undoubtedly has great potential. That
certain tumors in human patients are colonized by bacteria demonstrates that future
implementation of such a therapeutic option is realistic.
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5.3 Live Attenuated Viral Vaccines and Viral
Vaccine Vectors
5.3.1 Classical Viral Vaccines
Almost all human and veterinary vaccines against viral diseases which are in use
today are live attenuated or inactivated virus vaccines. Live virus vaccines are either
derived from related low pathogenic viruses which enable cross-protection against
the highly pathogenic virus strains (like the cowpox or vaccinia virus for vaccination
against variola virus that causes smallpox) or derived by undirected attenuation of
the viruses. Since they were all developed at a time when knowledge about the virus
genomes and mechanisms of virulence were still lacking, mutagenesis of viruses
was relatively random. In the past, attenuation of a virus was achieved by passaging
in embryonated eggs or in animals of different vertebrate species followed by
cell culture adaption. Later, with the establishment of standardized cell culture
techniques, live virus vaccines were propagated in primary cells like chicken
embryonic fibroblasts and human diploid cell lines (e.g., MRC-5) which have
a definite life span. To facilitate the process of vaccine production, these cells are
now successively being replaced by continuous cell lines (CCLs) due to improved
characterization of these cells and widened analytical technologies able to deter-
mine their possible oncogenic potential. Thus far, only a small number of human
vaccines are produced in CCLs (Gregersen et al. 2011). The African green monkey
kidney cell line Vero is now the most widely accepted CCL by regulatory authorities
and has been used for over 30 years for the production of polio and rabies virus
vaccines (Barrett et al. 2009). Furthermore, vaccine manufacturers of seasonal and
pandemic influenza vaccines are at various stages of developing cell-derived
vaccines (Pandey et al. 2010). Vero cells or Madin-Darby canine kidney (MDCK)
cells are often the CCLs of choice (Govorkova et al. 1996; Hu et al. 2011).
Current live viral vaccines are attenuated strains of poliovirus as well as measles,
mumps, or rubella virus. In some countries, the latter are given as triple vaccine,
called the MMR vaccine. These vaccines have been applied successfully and
brought the world closer toward eradication of additional viral diseases, besides
smallpox. Thus far, polio is eliminated from most parts of the world. Some
European countries claim the eradication of measles virus. These achievements
were possible because these viruses are restricted to the human host and do not
persist in an animal reservoir. In addition, only one viral serotype (variola, mumps,
measles, rubella) or very few serotypes (polio) exist. Thus, it is possible to induce
protective antibody titers with a relatively simple vaccine composition. T-cell
immunity is only known to play a role in the induction of protective immunity
against measles virus (Griffin and Pan 2009), while the role of T cells for immunity
against other viruses is still not clear.
Unfortunately, some countries still remain endemic for measles virus due to
various factors, such as political problems, inappropriate health care systems, socio-
ethical reasons, or inherent biological characteristics of the virus (Chumakov et al.
2007). However, also in some industrialized countries, compliance with routine
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vaccination of children has ceased to some extent. Hence, efforts of politics and
health care professionals on the one hand and also the development of new vaccines
are necessary in order to achieve the goal of global eradication of such viruses. For
example, research on measles vaccines now includes also the development of DNA
vaccines, subunit vaccines, and virus-vectored vaccines (Griffin and Pan 2009).
Furthermore, the development of robust vaccines and simple application
procedures is of great importance. In this regard, the development of thermostable
vaccines or vaccines for needle-free application, e.g., aerosol administration, is
in progress (Higginson et al. 2011). Moreover, the safety of measles vaccine in
HIV-infected persons has to be improved (Strebel et al. 2003). Eradication of
poliovirus was almost achieved using the trivalent polio vaccination. However,
now, the monovalent oral polio vaccine (OPV) or inactivated polio vaccine (IPV)
shall enable the complete eradication of polio (Ehrenfeld et al. 2009). Many
live vaccines are in use for livestocks like bovine respiratory syncytial virus for
cattle or calicivirus in cats. Thus far, the most successful live viral vaccine is the
“Rinderpest” vaccine. It has succeeded to completely eradicate the disease in 2011.
The use of an inactivated virus as vaccine is an alternative to the application of
viral LAV. One advantage is that pathogenic viral isolates can be used. Today,
inactivated vaccines are produced against tick-borne encephalitis virus, hepatitis
A virus, seasonal influenza, Japanese encephalitis virus, rabies and yellow fever,
and a spectrum of veterinary viral diseases. Inactivated vaccines have the advantage
of increased safety since they are not able to replicate in cells of the vaccinated host
and therefore do not spread to contacts. However, due to their replication defi-
ciency, such vaccines stimulate mainly antibody responses. Moreover, during the
inactivation process, e.g., the action of formaldehyde, the antigenicity of the
vaccine might be reduced due to the destruction of protective epitopes (Fraenkel-
Conrat and Mecham 1949; Metz et al. 2003). Thus, inactivated viruses often do not
reach the same efficacy as live attenuated virus, and a protective immune response
is not always elicited (Fig. 5.3).
The efficacy obtained with live virus vaccines in some cases prevented further
development of inactivated vaccines. However, the use of adjuvants, alternative
inactivation procedures, or vaccine compositions may allow the generation of new
inactivated vaccines with increased efficacy, able to induce antibody as well as
T-cell-mediated immune responses (Amanna and Slifka 2009). Nevertheless,
despite improved safety requirements, research on live attenuated viruses is also
maintained. For instance, a cold-adapted seasonal influenza vaccine has recently
been approved in the USA (Kreijtz et al. 2009).
5.3.2 Recombinant Antiviral Subunit Vaccines
Recombinant biotechnology allowed the development of two successful viral
subunit vaccines for humans, against the hepatitis B virus (HBV) and the human
papillomavirus (HPV). The HBV vaccine was registered in 1984. It is highly
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protective and reduced in endemic areas dramatically hepatocellular carcinoma that
is a sequel of chronic HBV infection. The HBV vaccine is produced in yeast or
mammalian CHO cells and consists of a recombinant surface protein of the virus,
the HBsAg (McAleer et al. 1984; WHO 2009). The two major yeast-derived
hepatitis B vaccines that are licensed in most countries are given as a monovalent
vaccine; however, formulations with a hepatitis A vaccine are also available
(Previsani and Lavanchy 2002). The HPV vaccine is directed against virus-induced
cervical cancer, some vulvar and vaginal cancers and some genital warts in young
women and men. Two prophylactic HPV vaccines were approved in Europe and the
USA in 2007. They both target the HPV serotypes 16 and 18 or additionally 6 and
11 and consist of the yeast or insect cell-produced shell L1 protein that self-
assembles into virus-like particles (GlaxoSmithKline 2011; Merck&CO 2011;
WHO publication 2008).
5.3.3 Recombinant Viral Vectors for Novel Vaccine Developments
Vaccines against a range of viral diseases are not yet available. This does not only
concern new emerging viruses like West Nile virus or newly arising pandemic
influenza viruses, e.g., H5N1 or H1N1, but also HIV and zoonotic viruses. Such
viruses often establish quickly a quasi-species in the host with a variant serology as
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Fig. 5.3 From naked adjuvanted vaccines to live viruses—the balance between genetic complexity,
strong immune response, and safety. There is an intrinsic mismatch between safety on the one side
and potent immune induction translating into protection on the other side. Highly attenuated
replication-defective viral vectors have been developed as a system balancing the benefit of
maximized immunogenicity and strongest safety. AS01 adjuvant system 01, MF59 oil-in-water
emulsion adjuvant, VLP virus-like particle, AdV adenovirus, MVA modified vaccinia virus Ankara,
AAV adeno-associated virus, VEE Venezuelan equine encephalitis virus
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an immune escape mechanism against host immune surveillance. This unfortu-
nately includes vaccine-induced immunity, making conventional vaccine develop-
ment extremely difficult. Thus, novel vaccines based on recombinant microbes
define nowadays future developments to conquer such diseases. Different viruses
are now exploited for the development of recombinant vaccines that include
members of the family of poxvirus, adenovirus, lentivirus, retrovirus, alphavirus,
rhabdovirus, as well as vesicular stomatitis virus (Fig. 5.4). Here, the virus builds
the backbone of a prophylactic or therapeutic vaccine for the delivery of heterolo-
gous antigens. The large panel of different viruses exhibiting different features
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Fig. 5.4 Human and veterinary viral vaccine vectors. Different viruses are developed as viral
vector vaccines. Some are investigated in clinical trials directed against either pathogens such as
viruses, bacteria, and parasites or other diseases (e.g., cancer, allergy)
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provides the possibility to exploit diverse immune-stimulating capacities as well as
the potential to deliver antigens to different immune inductive sites. Together with
prime–boost applications as well as adjuvant delivery, a wide range of possibilities
are provided to suffice requirements to fight many particular diseases.
Several recombinant vaccines have been successfully introduced into the veteri-
nary practice. Canarypox and fowlpox vector vaccines, baculovirus-expressed viral
antigens, and even DNA vaccines build the second generation of licensed veteri-
nary vaccines (Meeusen et al. 2007). Vector vaccines for humans are not yet
approved, but promising preclinical and clinical data have been obtained and will
be discussed below.
5.3.3.1 Attenuated Vaccinia Viruses
During the vaccination campaign against smallpox, severe side effects were
tolerated. Such side effects included generalized vaccinia, unwanted spreading to
unprotected contact persons, or even life-threatening reactions like eczema
vaccinatum, vaccinia necrosum, and postvaccinal encephalitis. However, despite
sporadic occurrence of zoonotic poxvirus infections and the threat of bioterrorism
today, such side effects are nowadays intolerable. Therefore, besides the continuous
use of the vaccinia virus (VACV) vaccine Dryvax for certain person groups in the
USA, attenuated strains have been developed. These are the modified vaccinia virus
Ankara (MVA) derived from the chorioallantois virus strain Ankara (Mayr et al.
1975), the New York VACV (NYVAC) based on the Copenhagen strain of VACV
(Tartaglia et al. 1992), and LC16m8 derived from the VACV Lister strain (Kenner
et al. 2006).
Like conventional VACV, MVA and NYVAC potently induce humoral and
cellular immune responses. However, these vaccines considerably differ in their
immune-stimulating capacity. MVA was generated by passaging the virus more
than 500 times in chicken embryonic fibroblasts, whereby it gained many deletions
and point mutations resulting in the loss of about 15 kb of DNA in comparison to its
parental strain. In contrast, NYVAC received deletions of 18 particular genes. In
both viruses, the function of several immune suppressive genes was lost. As a result
of their genetic diversity, MVA and NYVAC differentially stimulate the immune
response of the host. For example, distinct gene expression profiles were induced
upon infection of human monocyte-derived dendritic cells (Guerra et al. 2007;
Najera et al. 2006). Moreover, a parallel comparison of both vectors to determine
vaccine efficacy in a macaque HIV model showed a more CD4+ T-cell-driven
immune response for NYVAC, whereas MVA induced CD8+ as well as CD4+ T-
cell responses to the heterologous vaccine antigens (Mooij et al. 2008). The
molecular and immunological basis of innate and adaptive immune stimulation of
these viruses is now under intense investigation. Interestingly, MVA has a unique
ability to induce type I interferons and a spectrum of chemokines and cytokines in
contrast to VACV (Guerra et al. 2007; Lehmann et al. 2009; Waibler et al. 2007).
Due to their genomic deletions, MVA and NYVAC have lost the capacity to
replicate in most mammalian cells and consequently cannot spread in vivo (Drexler
et al. 1998; Gomez et al. 2007; Meyer et al. 1991; Tartaglia et al. 1992). Both
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viruses were tested in several animal models and found to be highly attenuated in
comparison to VACV. Moreover, MVA has already been used in humans. It was
proven to exhibit an excellent safety profile when applied to 120,000 humans
including high-risk patients still during the poxvirus eradication program (Mayr
et al. 1978). Later, several phase I clinical trials with different MVA vector
vaccines administered at high doses confirmed this safety profile of MVA (Goepfert
et al. 2011; von Krempelhuber et al. 2010; Wilck et al. 2010). In comparison with
other viral vectors, it is of note that MVA and NYVAC like other poxviruses
replicate exclusively in the cytoplasm of infected cells making a gene transfer
event into the host cell genome unlikely.
Despite the lack of productive infection, MVA and NYVAC exert a full gene
expression profile and are suitable to mediate high-level production of recombinant
antigens (Sutter and Moss 1992; Tartaglia et al. 1992). Well-defined protocols for
generation of recombinant viruses are established using homologous recombination
technology and plaque selection with the help of different marker genes (Carroll
and Moss 1995; Staib et al. 2000). More recently, recombinant VACV and MVA
vaccines have been generated by the use of bacterial artificial chromosomes which
further simplifies the construction of vector vaccines (Cottingham et al. 2008; Domi
and Moss 2002). The viruses tolerate large inserts of foreign sequences into their
double-stranded DNA genomes and are normally very stable. MVA can be pro-
duced in large amounts and can even be used as dried vaccine. Thus, it will be
suitable also for the application in areas where the cooling chain cannot be
guaranteed. In addition, mucosal needle-free application of freeze-dried MVA
into mice clearly demonstrated the potency of this formulation to induce immune
responses comparable to parenteral application. Protection against lethal bacterial
and viral challenges was generated this way (Kastenmuller et al. 2009). These
features proof recombinant MVA or VACV to be simple and safe vaccine platforms
for general application. Both MVA and NYVAC were developed as vector vaccines
against a diverse set of infections, cancer, and allergic diseases. Besides the use of
MVA directly as poxvirus vaccine, MVA-based vector vaccines against HIV,
malaria, and different cancers and allergies are investigated preclinically and also
in clinical phase I and/or II trials (Albrecht et al. 2008; Gomez et al. 2011).
5.3.3.2 Avipoxviruses
Canarypox and fowlpox are avipoxviruses which have been used since some time
as vector vaccines. Both avipoxviruses have a strict host tropism to birds but
contain the ability to infect mammalian cells and strongly express heterologous
antigens without completion of the virus life cycle. This constitutes an important
safety feature for these live attenuated virus vectors. Canarypox was shown to elicit
humoral and cellular immune responses in vaccinated subjects (Zanotto et al.
2010). Interestingly, recombinant canarypox was found being able to induce
a 100-fold stronger protective immune response compared to a similar fowlpox
vaccine (Taylor et al. 1991). Today, several canarypox-based veterinary vaccines
are in routine use (Poulet et al. 2007), of which most are based on the ALVAC
strain, a plaque isolate of the canary vaccine Kanapox. For humans, an ALVAC-
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based HIV vaccine (ALVAC-HIV, vCP1521) expressing the glycoprotein gp120 of
clade B/E is currently tested in a phase III clinical trial (Rerks-Ngarm et al. 2006).
In contrast to a trial where the recombinant vaccine was given alone, a prime–boost
regimen together with a recombinant HIV glycoprotein subunit vaccine
(AIDSVAX) gave encouraging results. In this efficacy trial performed in Thailand,
HIV acquisition was significantly reduced in the vaccine group (Vaccari et al.
2010).
5.3.3.3 Measles Viruses
Measles virus, also known as rubeola or morbilli, is an enveloped, single-stranded,
negative-sense RNA virus which infects the respiratory system. It belongs to the
family Paramyxoviridae of the genus Morbillivirus. In developed countries, most
children are immunized against measles. However, worldwide, approximately
200,000 children die of measles each year. Immune responses induced by routine
vaccination represent a problem for the use of recombinant measles vector
vaccines. On the other hand, the extensive clinical experience with the adapted
measles vaccines, their rare side effects, and their capacity to induce a strong often
lifelong immunity renders measles virus highly suitable as a vaccine vector. To use
a nonsegmented negative-strand RNA virus (Mononegavirales) as vector is possi-
ble nowadays by state-of-the-art molecular methods to produce cDNA clones.
These technologies allow site-directed mutagenesis to study gene functions as
well as to insert foreign coding sequences to develop multivalent vaccines against
measles and other pathogens. The use of measles virus as vector was experimen-
tally promoted by its high genetic stability, which is unexpected for RNA viruses,
and by its acceptance of foreign sequences. For quite a while, it was not possible to
convert measles virus into a vaccine vector, but in the meantime, appropriate
replicons, helper cells, and helper viruses were constructed (Collins et al. 1993,
1991; Conzelmann and Schnell 1994; Martin et al. 2006; Schneider et al. 1997;
Sidhu et al. 1995; Takeda et al. 2005). The newly developed systems allow the
insertion of additional transcription units for heterologous antigens. The maximal
insertion capacity tolerated by the virus is 6 kb, and expression level of the inserted
gene depends on the position within the viral genome (Billeter et al. 2009;
Hangartner 1997; Singh et al. 1999; Wang et al. 2001; Zuniga et al. 2007).
Measles-based vector vaccines are considered as candidates for multivalent vector
vaccines expressing antigens of hepatitis B (del Valle et al. 2007; Singh et al. 1999),
SIV/HIV (Brandler and Tangy 2008; Lorin et al. 2004; Tangy and Naim 2005;
Wang et al. 2001; Zuniga et al. 2007), West Nile, Dengue virus (Brandler and
Tangy 2008; Despres et al. 2005), and SARS coronavirus (Liniger et al. 2008).
Several studies in mouse models have shown that recombinant measles vaccines are
capable of inducing humoral immunity against both measles and heterologous
antigens (de Vries et al. 2008). The first candidate vaccine “HIV-measles,” which
was developed in the last few years by the Tangy group at the Pasteur Institute,
should enter soon into the clinical testing phase.
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5.3.3.4 Yellow Fever Virus
Yellow fever is an acute viral hemorrhagic disease caused by an enveloped, single-
stranded, positive-sense RNA virus of the Flaviviridae family. Surviving an infec-
tion by yellow fever virus results in lifelong immunity, and normally no permanent
organ damage is encountered in such individuals (Schmaljohn and McClain 2011).
The original yellow fever vaccine is a live attenuated virus based on the 17D yellow
fever virus strain (YFV-17D). It was developed almost 70 years ago by empirical
methods and is still considered to be one of the safest and most effective virus
vaccines. Starting from this vaccine, live attenuated chimeric viruses were con-
structed by replacing the genes coding for premembrane (prM) and envelope (E)
proteins of the YFV-17D vaccine strain with such of heterologous flaviviruses
(ChimeriVax technology) or the gene Japanese encephalitis virus (JE) encoding
the JE preM–Env protein (Draper and Heeney 2010). The latter chimera has
completed phase III trials and is currently in preregistration. The JE vaccine,
previously known as ChimeriVax-JETM, is supposed to become the first approved
human viral vector vaccine (Appaiahgari and Vrati 2010).
5.3.3.5 Adenoviruses
Human adenoviruses belong to the family Adenoviridae. Viruses of this family
infect both humans and animals. Adenoviruses are nonenveloped icosahedral
viruses assembled from a nucleocapsid that harbors the double-stranded linear
DNA genome. There are 53 serotypes of adenoviruses in humans with variable
morphology (Kaufman 2011). The virus is responsible for 5–10% of ocular,
respiratory, or gastrointestinal epithelium infections in children and also adults.
Already in 1977, a cell line was established that enabled the production of recom-
binant adenoviruses in a helper-free environment. Since this landmark, adenoviral
vectors have received attention as gene transfer agents for gene therapy and for
vector-based vaccinations (Randrianarison-Jewtoukoff and Perricaudet 1995).
Attenuation is usually achieved by deleting the E1A gene that is known to be
essential for adenoviral replication (Carlock and Jones 1981; Gaynor and Berk
1983). The DE1A vectors are able to infect cells without causing any cellular
damage. In the first vector generation, E1 and E3 were deleted (DE1/E3) because
the E3 region is not essential for in vitro vector production. The adenovirus vector is
able to deliver genes with nearly 100% efficiency to a wide range of cell types
including dividing or nondividing cells as well as primary cells, and it is possible to
produce extremely high viral titers. Adenoviral vectors provide a capacity of up to
8 kb of foreign recombinant genes. In the classical adenovirus vector generation,
the recombinant genes are inserted into the deleted E1A region of a viral cDNA by
in vitro ligation and homologous recombination protocols (Wolff and Lederberg
1994). A new approach allows the generation of recombinant adenoviruses by Tn7-
mediated transposition in E. coli (Richards et al. 2000). For the viral production,
normally modified 293 cells are utilized. These cells are stably transfected with the
E1A region of the adenoviral genome and allow the vector to replicate and mature.
The resulting vector particle prepared from this cell line will lack the E1A region
and remain replication deficient. As with any viral vector system, it has to be
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ensured that the produced vector is not contaminated with the wild-type virus. In the
adenoviral system, two homologous recombination events must occur to restore
wild-type virus rendering this event highly unlikely.
Adenovirus vectors strongly induce the innate arm of the immune system that
results in inflammation of infected tissues and efficient clearance of administered
vectors (Muruve 2004). Adenovirus vector vaccines are developed against a variety
of different infectious diseases and have entered clinical trials for malaria (phase I),
HIV-1 (Fitzgerald et al. 2011), different cancers, and others malignancies (CR
Health Net 2011).
5.3.3.6 Virus-Like Particles and Other Viral Vector Systems
Virus-like particles (VLPs) are also considered as vector vaccines despite they are
nonliving empty viral particles. These so-called pseudoviruses are noninfectious
because they lack any viral genetic information which is normally packaged into
such particles. For this technique, the capacity of viral structural proteins such as
envelope or capsid to self-assemble into VLPs was exploited (Kirnbauer et al. 1992;
Kost and Condreay 1999; Valenzuela et al. 1982). VLPs of HBsAg derived from
HBV were already described over 40 years ago from infected patient sera (Bayer
et al. 1968). Nowadays, VLPs are produced for the licensed HPV vaccine and
additionally from a whole variety of other virus families including Parvoviridae
(e.g., adeno-associated virus), Retroviridae (e.g., HIV), Polyomaviridae (e.g., JC
virus) (Chang et al. 2011), Paramyxoviridae (e.g., Nipah virus) (Walpita et al.
2011), and Flaviviridae (e.g., hepatitis C virus). Despite their limited immune
stimulatory capacity, VLPs are attractive vaccine candidates due to their higher
safety level compared to LAV (Fig. 5.3). VLPs can be produced in different cell
culture systems including mammalian and rodent cell lines, insect cell lines, yeast,
and also plant cells (Santi et al. 2006). For VLP vaccines, the foreign antigen is
normally fused to the viral envelope protein or to a membrane domain, guiding and
anchoring the antigen to the surface of the viral particle. The VLP presents the
antigen to the immune system in its natural length and native structure. The
particulate nature of the vaccine promotes immune recognition of the heterologous
antigen (Bach et al. 2009; Hunter et al. 2011; Li et al. 2004; Nikles et al. 2005;
Walpita et al. 2011). Until today, there are different antigens tested for their
capacity to induce a protective immunity or to break immunological tolerance.
Thus far, no VLP-based vector vaccine has entered clinical testing phase.
A new vaccine approach against HIV was developed in the macaque AIDS
model using pathogenic SIVmac239 as disease-inducing agent. For vaccination,
rhesus cytomegalovirus (RhCMV), a replication competent and persistent but
normally harmless virus, was equipped with a set of SIV antigens. This vaccine
was shown to completely control SIV infection and spreading in some of the
infected animals which was normally not achieved with the more common
prime–boost strategies with highly immune activating but replication incompetent
viral vectors. The continuous antigen delivery by the RhCMV/SIV vaccine in
combination with the ability to stimulate an effector memory T-cell response was
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suggested as reason for this vaccination success (Hansen et al. 2011). Such vector
systems might provide a new way for the development of effective HIV vaccines.
5.3.4 Oncolytic Viruses
In the last century, clinical observations reported that cancer regression coincided
with virus infections. However, tumor regression was mostly transient and incom-
plete (Kelly and Russell 2007; Sinkovics and Horvath 1993). At that time, there was
no knowledge on virus infections, immune responses, and the correlate to tumor
regression, and therefore, the use of oncolytic viruses today demands the investiga-
tion of those parameters. Reovirus, vaccinia, measles, adeno, herpes, vesicular
stomatitis virus, as well as Newcastle disease virus, are the viruses mainly consid-
ered for therapies of cancer by oncolysis. The first approved oncolytic virus H101
has been approved in 2005 in China but not in Europe or the USA (Kirn 2006). It is
a DE1B adenovirus variant. For the improvement of safety, i.e., the tumor-specific
infection and replication as well as efficacy, i.e., destruction of the tumor and
eventually also metastases, it is essential to understand viral tropism and host
restriction in addition to the influence of the molecular phenotype of the tumor.
Techniques to specifically modify viruses for a rational design and the development
of safe and efficient oncolytic viruses are already available. For instance,
retargeting through modification of viral envelope proteins or their substitutions
as well as activation or restriction of viral replications through specific viral gene
deletions are necessary to generate safe and tumor-specific viruses. In addition,
arming and shielding oncolytic viruses will improve oncolytic efficacy. Arming
refers to equipping the virus with genes encoding prodrug-converting enzymes or
immune stimulatory proteins to enhance antitumor activity. Shielding can be done
chemically or biologically by using different viral serotypes to prevent neutraliza-
tion by preexisting virus-specific antibodies (Cattaneo et al. 2008).
Recent reports indicate synergistic effects between direct viral oncolysis and
activation of specific antitumor immune responses. This suggests the inclusion of
immunotherapeutic approaches into viral antitumor therapy (Boisgerault et al.
2010). Among various immunomodulatory proteins that have been proposed,
the most successfully employed immune-stimulating factor in advanced oncoly-
tic viruses is the granulocyte-macrophage colony-stimulating factor (GMCSF).
A second molecule is interferon-ß, although recombinant viruses harboring the
corresponding gene have not entered clinical trials yet (Melcher et al. 2011).
Besides, proteases, glycosidases, and strategies that target angiogenesis are also
tested with respect to their antitumor activity (Boisgerault et al. 2010).
5.4 Animal Models
To study the safety and efficacy of a new vaccine candidate, preclinical evaluation
in animals precedes in most cases testing in humans. Various mouse models are
often used to establish first proof of concept for a new vaccine in vivo with regard to
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its safety and efficacy. Since pathogen–host interaction differs between mouse and
human, careful selection of the pathogen for challenge experiments and the appro-
priate mouse strain (or an alternative animal model) is necessary in order to obtain
relevant data.
For example, in the case of efficacy testing of poxvirus vaccines, the most
common challenge model uses the lab-adapted VACV strain Western Reserve in
mice. Even though special safety equipment is demanded for work with ectromelia
virus, however, as the natural mouse pathogen causing mousepox, this virus
resembles much more the course of disease progression of a variola virus in humans
than the Western Reserve strain. To define the best route of challenge, virus
administration is also important. Besides footpad inoculation, intranasal infection
appears to mimic a more natural route of poxvirus infection. Thus, this virus–
animal model represents an optimal small animal model to study MVA and ortho-
poxvirus immunogenicity and vaccine success (Paran et al. 2009; Paran and Sutter
2009). Other viruses, e.g., HIV, measles virus, and Ebola virus, cannot infect or
replicate in mice due to strict host specificity. For such viruses, other target animals
such as monkeys are needed. In the case of HIV, infection of macaques with the
simian immunodeficiency virus (SIV) is still an important animal model for the
understanding of HIV pathogenesis and the development of novel HIV vaccines.
A natural SIV variant defective in the Nef gene function was found to induce
protective immunity against an SIV challenge and thus can provide a valid tool to
study the immune parameters that confer protection against the challenge virus
(Daniel et al. 1992). However, due to ethical concerns and high costs, low numbers
of animals can be used in experimental settings. An alternative attempt is made to
develop new mouse strains transgenic for human components. For example,
a mouse transgenic for the human SLAM receptor enabled measles virus infection
Table.5.2 Overview of the features of viral vectors
Human adenovirus
(HAdV)
Modified
vaccinia virus
Measles virus Yellow fever Canarypox
virus
Family Adenoviridae Poxviridae Paramyxoviridae Flaviviridae Poxviridae
Genus Mastadenovirus Orthopoxvirus Morbillivirus Flavivirus Avipoxvirus
Species Six species (A–F) Vaccinia virus Paramyxoviruses Natural forms:
urban yellow fever,
sylvatic yellow fever
For vaccines used:
17D yellow fever
virus strain
Fowlpox
virus
Serotypes 53 Serotypes
Genome 34–43 kb double-
stranded DNA
178 kb
double-
stranded DNA
Single-stranded,
negative-sense
RNA
Single-stranded,
positive-sense RNA
Double-
stranded
DNA
Cellular
receptors
Coxsackie adenovirus
receptor, heparin-
sensitive receptor,
CD46, CD80, and CD86
Unknown SLAM and
CD46
In discussion:
Glycosaminoglycans
Insert
capacity
~7.5 kb 25 kb 6 kb
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and replication in otherwise resistant mice (Ohno et al. 2007). Additionally, immu-
nogenic parameters that would also be representative for humans cannot always be
found in animal models. Therefore, so-called humanized mice are developed which
lack parts of their own immune system and thus can be reconstituted with human
hematopoietic stem cells from which functional human immune cells can develop
(Legrand et al. 2009). Similarly, humanized mice have been successfully tested in
infection experiments using S. typhi, a bacterial pathogen that is exclusively
restricted to humans (Song et al. 2010). Although the procedure to humanize
mice is experimentally still very challenging, it is reasonable to expect that this
system will be more and more introduced into testing of vaccines and therapeutics
for intended human use.
5.5 Conclusion and Outlook
The use of LAV has made an indispensable contribution in the fight against
infectious diseases. While initially undirected mutagenesis or extended passaging
was employed to render the vaccine safe, today, modern molecular genetics allows
the rational design of live microbes as a more efficient and safer vaccine or as vector
systems for the delivery of heterologous prophylactic and therapeutic
macromolecules. A number of bacterial, viral, and in some cases eukaryotic vector
systems are considered as prospective carriers for protein, nucleic acid, or polysac-
charide cargos. In addition to vaccination, live vectors offer new routes for the
treatment of various disorders, such as cancer, gene deficiencies, allergies, or
autoimmune diseases. However, the introduction of a new generation of recombi-
nant live vector systems into medical practice is a long endeavor. In order to
meet all requirements for approval, the safe, efficacious, and controlled use of
such systems has to be carefully demonstrated in preclinics and the clinics. In
addition, risks associated with genetically modified LAV, which might be released
into the environment, have to be comprehensively assessed. The recent introduction
of several recombinant bacterial and viral LAV into practice is a valuable proof of
concept and will help to pave the roads for the development of such vaccines in the
future.
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